Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide plus Lobaplatin vs Cisplatin with TRT in Limited SCLC
NCT03613597Phase 2Unknown
- Sponsor
- Guizhou Medical University
- Start
- Jun 2018
- Primary completion
- Jan 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised trial of lobaplatin in small cell lung cancer (SCLC) (2 arms), sponsored by Guizhou Medical University. Primary endpoint: Progression-free survival at 12 months. Status: unknown.
02
Drugs
lobaplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03613597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613597.